Beyond one-size-fits-all: single-cell transcriptomic signatures predict drug efficacy and reveal responder subgroups in endometriosis

Raúl Pérez-Moraga, Cemsel Bafligil, Sarah Harden, Santiago García-Martín, María José Jiménez-Santos, Ioanna Tiniakou, Sophie Ribeiro-Volturo, Line Gies, María Teresa Pérez Zaballos, Cristina Fernández-Molina
In: bioRxiv · 2025 · doi:10.64898/2025.12.09.693218 · W7114928105
article OA: green CC0
🔓 Open OA copy View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

Single-cell transcriptomics identified drug candidates and patient subgroups by revealing drug efficacy predictions and cell-type-specific vulnerabilities in endometriosis tissues.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Abstract Endometriosis affects ∼10% of reproductive-age women, yet targeted non-hormonal therapies remain unavailable, and treatment response is highly variable. Here, we apply a single-cell framework to resolve therapeutic heterogeneity at a resolution previously unattained in drug development efforts. Using scRNA-seq profiles from eutopic and ectopic tissues, combined with a machine learning-based drug response model, we identified compounds predicted to revert disease-associated transcriptional states and map cell-type-specific vulnerabilities across patients and tissues. Our analysis revealed pronounced tissue-specific and inter-patient heterogeneity in predicted responses. Stromal, endothelial, and stem cell populations emerged as the dominant therapeutic targets, collectively revealing selective sensitivity to two recurrent drug classes, histone deacetylase and tubulin polymerisation inhibitors. Transcriptomic comparison of predicted responders and non-responders to these drugs pointed to conserved molecular programmes involving extracellular matrix remodelling, angiogenesis, and proliferative activation. These signatures were shared between eutopic and ectopic stromal compartments, supporting the feasibility of assessing therapeutic response using readily accessible eutopic tissue. Our findings show that this single-cell framework can dissect therapeutic heterogeneity in endometriosis, support the development of precision non-hormonal therapies and identify responder subgroups relevant for patient stratification. Together, these results highlight that underlying molecular diversity in endometriosis necessitates therapeutic approaches beyond a one-size-fits-all model.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (74)

Source provenance

europepmc
last seen: 2026-06-04T01:45:00.660873+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK